Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adjuvant Palbociclib in Elderly Patients With Breast Cancer (Appalaches)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03609047
Recruitment Status : Recruiting
First Posted : August 1, 2018
Last Update Posted : July 25, 2019
Sponsor:
Collaborators:
Pfizer
Swedish Association of Breast Oncologists
International Breast Cancer Study Group
German Adjuvant Breast Cancer Group
SOLTI Breast Cancer Research Group
UNICANCER
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC

Brief Summary:
Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Stage II Breast Cancer Stage III Drug: Palbociclib Drug: Docetaxel / cyclophosphamide Drug: doxorubicin/cyclophosphamide Drug: epirubicin/cyclophosphamide Drug: paclitaxel Phase 2

Detailed Description:

The primary objective of this trial is to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast cancer.

This is a two-arm open-label multi-center randomized (2:1) non-comparative phase II study in elderly patients with stage II/III, ER+, HER2- early breast cancer for whom treatment with chemotherapy is indicated.

Patients will be randomized with a 2:1 allocation rate to the following treatment arm:

  • experimental palbociclib arm: Standard adjuvant endocrine therapy for a duration of at least 5 years + palbociclib for a total duration of up to 2 years.
  • control chemotherapy arm: adjuvant chemotherapy (4 cycles of docetaxel/doxorubicin/epirubicin-cyclophosphamide; or of weekly paclitaxel D1, D8, and D15 q3w if a 3 weekly schedule is not desired), followed by standard adjuvant endocrine therapy for a duration of at least 5 years.

The primary endpoint of the study is the 3-year D-RFI rate in the experimental arm.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 366 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized 2:1
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS With High-risk ER+/HER2- Early Breast Cancer
Actual Study Start Date : June 14, 2019
Estimated Primary Completion Date : June 13, 2024
Estimated Study Completion Date : June 13, 2031

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Palbociclib

Arm Intervention/treatment
Experimental: experimental palbociclib arm
Standard adjuvant endocrine therapy for a duration of at least 5 years + palbociclib (one capsule 125mg QD, orally, for 21 days followed by 7 days off treatment) for a total duration of up to 2 years.
Drug: Palbociclib
CDK4/6 inhibitor

Active Comparator: control chemotherapy arm

Adjuvant chemotherapy:

4 cycles docetaxel 75 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles doxorubicin 60 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles epirubicin 90 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles weekly paclitaxel 80 mg/m2 D1, D8, and D15 q3w

Followed by standard adjuvant endocrine therapy for a duration of at least 5 years.

Drug: Docetaxel / cyclophosphamide
Adjuvant Chemotherapy

Drug: doxorubicin/cyclophosphamide
Adjuvant Chemotherapy

Drug: epirubicin/cyclophosphamide
Adjuvant Chemotherapy

Drug: paclitaxel
Adjuvant Chemotherapy




Primary Outcome Measures :
  1. distant recurrence-free interval (D-RFI) rate [ Time Frame: 5 years after first patient inclusion ]

Secondary Outcome Measures :
  1. Breast cancer specific survival [ Time Frame: 5 years after first patient inclusion ]
  2. Overall survival [ Time Frame: 5 years after first patient inclusion ]
  3. Incidence of permanent treatment discontinuation [ Time Frame: 5 years after first patient inclusion ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   70 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women or men with stage II or stage III, early invasive breast cancer according to the UICC 8th edition for TNM classification
  • Histologically confirmed Estrogen Receptor ER+ (at least 10 % of cells staining positive for ER), Human Epidermal Growth Factor Receptor 2 (HER-2) negative, early invasive breast cancer based on results of local pathology. Testing may be performed on diagnostic core biopsy or resection specimen.
  • In patients with multicentric, multifocal and/or bilateral breast cancer, all histopathologically examined invasive tumors must meet pathologic criteria regarding ER and HER2-status described above.
  • Adjuvant chemotherapy indicated and feasible according to treating physician and patient, based on standard clinicopathological parameters (tumor size, lymph node involvement, general health status, proliferation marker, patient wish) and gene expression profile if available.
  • Adjuvant chemotherapy combining both anthracycline and taxanes considered not indicated or not feasible according to treating physician.
  • No evidence of macroscopic distant metastases, investigated according to local institutional guidelines.
  • Age ≥70 years
  • Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
  • Patient must have undergone breast +/- axillary surgery with curative intent for the current malignancy ≤8 weeks before randomization.
  • The maximum duration from last surgery to the start of the first adjuvant treatment is 9 weeks.
  • Patients must have sufficient resolution of any surgical side effects from the last surgery per physician assessment, with no active wound healing complications at the time of randomization.
  • Incentive to undergo adjuvant radiation therapy when indicated per local institutional guidelines.
  • Note: For patients in the palbociclib arm, radiation therapy when indicated has to start ≤9 weeks after last surgery. The endocrine therapy can be initiated during or after the radiation therapy but not later than 3 weeks after the last radiotherapy. Palbociclib has to start ≤3 weeks after the last radiotherapy. When radiation therapy is not indicated, endocrine therapy and palbociclib have to be initiated ≤9 weeks after last surgery.
  • Note: For patients in the chemotherapy arm, chemotherapy has to be the first adjuvant treatment and has to start ≤9 weeks after the last surgery. When radiation therapy is indicated, this treatment has to start ≤6 weeks after the last chemotherapy administration. Adjuvant endocrine therapy can be initiated during or after the radiation therapy but not later than 3 weeks after the last radiotherapy. When radiation therapy is not indicated, endocrine therapy has to be initiated ≤6 weeks after last chemotherapy administration.
  • Adequate organ function, evidenced by the following laboratory results within 3 weeks prior to inclusion:
  • Hemoglobin ≥ 9 g/dL
  • Absolute neutrophil count (ANC) ≥ 1500/mm3
  • Platelet count ≥ 100,000/mm3
  • Total bilirubin ≤ 1.5 upper limit of normal (ULN), or total bilirubin ≤ 3.0 × ULN in patients with documented Gilbert's Syndrome.
  • Glomerular Filtration Rate (GFR) ≥ 30 ml/min according to Modification of Diet in Renal Disease (MDRD) formula or Chronic Kidney Disease - Epidemiology Collaboration (CKD-EPI) formula or Cockcroft and Gault formula
  • Serum Glutamic Oxaloacetic Transaminase (Aspartate Transaminase), Serum Glutamic Pyruvic Transaminase (Alanine Transaminase) and alkaline phosphatase ≤ 2.5 × ULN
  • Patients must be able and willing to swallow and retain oral medication without a condition that would interfere with enteric absorption.
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
  • Before patient registration/randomization, written informed consent must be obtained according to ICH/GCP, and national/local regulations.

Exclusion Criteria:

  • Previous history of invasive breast cancer
  • Systemic anticancer therapy prior to the breast cancer surgery
  • Prior therapy with any Cyclin-Dependent Kinase (CDK)4/6 inhibitor
  • Concurrent investigational agent within 28 days of randomization
  • Concomitant anticancer treatment with the exception of bone antiresorptive agents or Luteinizing Hormone-Releasing Hormone agonists in male patients treated with an aromatase-inhibitor
  • History of allergic reactions attributed to compounds of chemical or biological composition similar to palbociclib or to chemotherapy components
  • Medications or substances that are potent inhibitors or inducers of CYP3A isoenzymes within 7 days of randomization (see Chapter 5.6.3 for list of CYP3A inhibitors and inducers)
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (including known HIV, active hepatitis B and/or hepatitis C infection), symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or uncontrolled diabetes.
  • Other malignancy within the last 5 years except: adequately treated non-metastatic non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ of the breast.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03609047


Contacts
Layout table for location contacts
Contact: EORTC HQ +3227741611 1745@eortc.org

Locations
Layout table for location information
Belgium
Cliniques Universitaires Saint-Luc Recruiting
Brussels, Belgium
Contact: Frank Cornelis         
Institut Jules Bordet-Hopital Universitaire ULB Recruiting
Brussels, Belgium
Contact: Lissandra Dal Lago         
U.Z. Leuven - Campus Gasthuisberg Recruiting
Leuven, Belgium
Contact: Hans Wildiers         
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Pfizer
Swedish Association of Breast Oncologists
International Breast Cancer Study Group
German Adjuvant Breast Cancer Group
SOLTI Breast Cancer Research Group
UNICANCER
Investigators
Layout table for investigator information
Study Chair: Hans Wildiers, MD, PhD KU Leuven

Layout table for additonal information
Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov Identifier: NCT03609047     History of Changes
Other Study ID Numbers: EORTC 1745-ETF-BCG
First Posted: August 1, 2018    Key Record Dates
Last Update Posted: July 25, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
Breast cancer
elderly patients
CDK4/6 inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Docetaxel
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Epirubicin
Palbociclib
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Myeloablative Agonists
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Protein Kinase Inhibitors